Opinion|Videos|June 17, 2024
Recent Updates from the postMONARCH Study
The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.
Advertisement
Advertisement
Related to this article
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5